Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...

The Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr) in combination with platinum and ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

BeiGene (BGNE) has received U.S. FDA approval for its cancer drug Tevimbra in combination with chemotherapy for certain ...

SAN MATEO, Calif., December 27, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd ...

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...

“Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition success ...

New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.